BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23149819)

  • 21. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
    J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
    Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Gao F
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
    Liu L; Chen F; Zhao J; Yu H
    Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer.
    Yoshida Y; Kaneko M; Narukawa M
    Int J Clin Oncol; 2020 May; 25(5):851-860. PubMed ID: 31950377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
    Shi Q; de Gramont A; Grothey A; Zalcberg J; Chibaudel B; Schmoll HJ; Seymour MT; Adams R; Saltz L; Goldberg RM; Punt CJ; Douillard JY; Hoff PM; Hecht JR; Hurwitz H; Díaz-Rubio E; Porschen R; Tebbutt NC; Fuchs C; Souglakos J; Falcone A; Tournigand C; Kabbinavar FF; Heinemann V; Van Cutsem E; Bokemeyer C; Buyse M; Sargent DJ
    J Clin Oncol; 2015 Jan; 33(1):22-8. PubMed ID: 25385741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
    Chirila C; Odom D; Devercelli G; Khan S; Sherif BN; Kaye JA; Molnár I; Sherrill B
    Int J Colorectal Dis; 2012 May; 27(5):623-34. PubMed ID: 22076612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
    Montagnani F; DI Leonardo G; Pino MS; Martella F; Perboni S; Ribecco A; Fioretto L
    Anticancer Res; 2016 Aug; 36(8):4259-65. PubMed ID: 27466541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer.
    Colloca GA; Venturino A; Guarneri D
    Int J Clin Oncol; 2019 Nov; 24(11):1406-1411. PubMed ID: 31289956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis.
    Colloca GA; Venturino A; Guarneri D
    Int J Clin Oncol; 2019 Mar; 24(3):231-240. PubMed ID: 30719690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.